The primary endpoint of the SOLTI-1805 TOT-HER3 trial was CelTIL score after one single dose27, a biological surrogate of response based on the percentage of tumor cellularity and the percentage of stromal TILs11,12,27. The gene discussed is ERBB3; the disease is neoplasm.